-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For Zilurgisertib Showing 99.9% Reduction In New HO Lesion Volume In Fibrodysplasia Ossificans Progressiva Patients At Week 24

Benzinga·06/15/2026 06:53:39
Listen to the news
  • - Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP
  • - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review